Filament Health Corp. (NEO:FH)

Market Cap	8.92M
Revenue (ttm)	616.68K
Net Income (ttm)	-4.97M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96,000
Average Volume	15,931
Open	0.0200
Previous Close	0.0150
Day's Range	0.0150 - 0.0200
52-Week Range	0.0150 - 0.0700
Beta	1.14
RSI	26.42
Earnings Date	Mar 31, 2025

About Filament Health

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, it provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquarter...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Benjamin Lightburn
• Employees: 13
• Stock Exchange: Cboe Canada
• Ticker Symbol: FH

Financial Performance

In 2024, Filament Health's revenue was 616,678, a decrease of -71.06% compared to the previous year's 2.13 million. Losses were -4.97 million, -6.61% less than in 2023.